XOMA CORPORATION

Analyst Reco. XOMA Corporation Nasdaq

Equities

XOMAO

US98419J4040

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-06 pm EDT			5-day change	1st Jan Change
25.1 ^USD	+0.44%		+0.08%	-0.08%

May. 09	Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M	MT
May. 09	XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target	Apr. 29	MT
HC Wainwright Adjusts Price Target on XOMA to $74 From $69, Maintains Buy Rating	23-08-09	MT
XOMA : Wedbush Suspended Coverage on XOMA	21-10-11	MT
XOMA : HC Wainwright Adjusts XOMA's Price Target to $69 from $56, Keeps Buy Rating	21-10-08	MT
XOMA : Aegis Capital Adjusts XOMA Price Target to $56 From $60, Maintains Buy Rating	21-09-09	MT
Wedbush Downgrades XOMA to Neutral From Outperform, Adjusts PT to $22 From $41	21-09-07	MT
XOMA : Wedbush Downgrades XOMA to Neutral From Outperform, Adjusts PT to $22 From $41	21-09-07	MT
XOMA : Aegis Capital Starts XOMA at Buy with $20.68 Price Target	21-06-29	MT
XOMA : Wedbush Adjusts XOMA's Price Target to $41 From $36, Citing Iscalimab, Cetrelimab Projections; Outperform Rating Kept	21-03-19	MT
XOMA : Wedbush Adjusts XOMA's Price Target to $36 From $29 on Vicineum Sales Forecast, Keeps Outperform Rating	20-11-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer